CAR T-Cell Therapy in Multiple Myeloma : Episode 3
CAR-T Therapy in Standard-Risk Multiple Myeloma: Rationale and Patient Preparation
Panelists discuss the rationale for considering chimeric antigen receptor (CAR) T-cell therapy in standard-risk multiple myeloma and how health care providers help patients understand and prepare for the decision to pursue CAR T-cell treatment.
Video content above is prompted by the following:
Dr Castaneda: Ask Jammie:
- What is the rationale for considering chimeric antigen receptor (CAR) T-cell therapy as a treatment in standard-risk multiple myeloma?
Dr Castaneda: Ask Jammie:
- How do you help patients understand the option of CAR T cell as a therapy, and what is your role in preparing them for this decision?
Recent Videos
Related Content
